Phio Pharmaceuticals is a biotechnology business based in the US. Phio Pharmaceuticals shares (PHIO) are listed on the NASDAQ and all prices are listed in US Dollars. Phio Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $6.16 |
|---|---|
| 52-week range | $3.90 - $29.04 |
| 50-day moving average | $5.31 |
| 200-day moving average | $7.68 |
| Wall St. target price | $72.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.92 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.16 from 2023-02-06
| 1 week (2023-01-31) | -1.00% |
|---|---|
| 1 month (2023-01-06) | 909.84% |
| 3 months (2022-11-08) | 976.92% |
| 6 months (2022-08-08) | 742.68% |
| 1 year (2022-02-08) | 601.59% |
|---|---|
| 2 years (2021-02-08) | 77.01% |
| 3 years (2020-02-07) | 7.45 |
| 5 years (2018-02-07) | 2257.198 |
| Gross profit TTM | $-8,886,000 |
|---|---|
| Return on assets TTM | -34.82% |
| Return on equity TTM | -62.93% |
| Profit margin | 0% |
| Book value | $11.88 |
| Market capitalisation | $7 million |
TTM: trailing 12 months
We're not expecting Phio Pharmaceuticals to pay a dividend over the next 12 months.
Phio Pharmaceuticals's shares were split on a 1:12 basis on 25 January 2023. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Phio Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Phio Pharmaceuticals shares which in turn could have impacted Phio Pharmaceuticals's share price.
Over the last 12 months, Phio Pharmaceuticals's shares have ranged in value from as little as $3.9 up to $29.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Phio Pharmaceuticals's is 1.3983. This would suggest that Phio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.